Abstract
PurposePrevious literature has reported contradicting results regarding the relationship between tumor volume changes during radiotherapy treatment for non-small cell lung cancer (NSCLC) patients and locoregional recurrence-free rate or overall survival. The aim of this study is to validate the results from a previous study by using a different volume extraction procedure and evaluating an external validation dataset.MethodsFor two datasets of 94 and 141 NSCLC patients, gross tumor volumes were determined manually to investigate the relationship between tumor volume regression and locoregional control using Kaplan–Meier curves. For both datasets, different subgroups of patients based on histology and chemotherapy regimens were also investigated. For the first dataset (n = 94), automatically determined tumor volumes were available from a previously published study to further compare their correlation with updated clinical data.ResultsA total of 70 out of 94 patients were classified into the same group as in the previous publication, splitting the dataset based on median tumor regression calculated by the two volume extraction methods. Non-adenocarcinoma patients receiving concurrent chemotherapy with large tumor regression show reduced locoregional recurrence-free rates in both datasets (p < 0.05 in dataset 2). For dataset 2, the opposite behavior is observed for patients not receiving chemotherapy, which was significant for overall survival (p = 0.01) but non-significant for locoregional recurrence-free rate (p = 0.13).ConclusionThe tumor regression pattern observed during radiotherapy is not only influenced by irradiation but depends largely on the delivered chemotherapy schedule, so it follows that the relationship between patient outcome and the degree of tumor regression is also largely determined by the chemotherapy schedule. This analysis shows that the relationship between tumor regression and outcome is complex, and indicates factors that could explain previously reported contradicting findings. This, in turn, will help guide future studies to fully understand the relationship between tumor regression and outcome.
Highlights
Tumor volume is a known prognostic factor for non-small cell lung cancer (NSCLC) patients [1,2,3]
The World Health Organization (WHO) performance status and the N-stage were significantly different between the two datasets (p = 0.004 and p < 0.001, respectively)
The dataset evaluated in the previous study, as well as a second dataset from a different institute, were evaluated using a manual volume extraction method to investigate the relationship between tumor regression and overall survival (OS) and locoregional recurrence-free rate (LRFR)
Summary
Tumor volume is a known prognostic factor for non-small cell lung cancer (NSCLC) patients [1,2,3]. The relationship between changes in tumor volume during the course of (chemo)radiotherapy remains unclear. Toxicity estimates, and adaptive radiotherapy strategies, it is important to understand and monitor tumor behavior over the course of treatment. A recent systematic review reports that the majority of retrospective studies found a significant correlation between gross tumor volume (GTV) prior to radiotherapy and overall survival (OS) [1]. The results for GTV changes during treatment were contradicting. The review describes a total of nine studies that investigated the relationship between GTV changes during treatment and OS. Most studies used computed tomography (CT) or 18F-FDG positron-emission tomography imaging to evaluate the changes [4]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.